<DOC>
	<DOCNO>NCT00122577</DOCNO>
	<brief_summary>This trial aim study antiviral activity , toxicity pharmacokinetic ( PK ) interaction tenofovir DF atazanavir enhance low dose ritonavir give alone concomitantly part salvage regimen HIV patient multiple failure , condition allow tease specific role atazanavir combine low dose ritonavir .</brief_summary>
	<brief_title>Efficacy Safety Tenofovir DF/Atazanavir Enhanced With Low Dose Ritonavir HIV-Infected Patients</brief_title>
	<detailed_description>When license , new drug widely use patient fail antiretroviral therapy , include patient multiple failure . In patient , multi-resistant virus , introduction one new drug salvage regimen infrequently result undetectable virus load plasma . Tenofovir DF atazanavir appear promising pharmacokinetic profile , activity , safety resistance property . In addition , pharmacokinetic data healthy volunteer suggest atazanavir could optimize add ritonavir low dose . Thus , one may speculate atazanavir pharmacokinetic antiviral activity could optimize add ritonavir low dose patient exhibit high rate protease inhibitor mutation . This protocol aim study antiviral activity , toxicity PK interaction , tenofovir DF atazanavir enhance low dose ritonavir give alone concomitantly part salvage regimen patient multiple failure , condition allow tease specific role atazanavir combine low dose ritonavir . EKG abnormality ( increase PR QTc interval ) observe normal volunteer treat atazanavir , therefore EKG safety monitoring perform subject study</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Males non pregnant female 18 year age old confirm laboratory diagnosis HIV infection document failure ( plasma HIV RNA level 10,000 copies/ml ) least two protease inhibitor ( ritonavir [ RTV ] must give dose 400 mg twice day ( bid ) , order qualify protease inhibitor study ) one nonnucleoside reverse transcriptase inhibitor ( NNRTI ) Ongoing antiretroviral therapy inclusion without change within last month No threshold CD4 cell count Patients naive atazanavir tenofovir DF Cardiomyopathy QTc interval 450 msec pause length 3 second screen EKG Heart rate 40 bpm Third degree heart block , clinical symptom potentially related heart block Ongoing immunotherapy include IL2 , interferon HIV specific vaccine Ongoing opportunistic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Treatment Failure</keyword>
	<keyword>tenofovir</keyword>
	<keyword>atazanavir</keyword>
</DOC>